CY1111409T1 - Μονοκλωνικα αντισωματα και θραυσματα αντισωματων μονης αλυσιδας εναντιον προστατικου μεμβρανικου αντιγονου κυτταρικης επιφανειας - Google Patents
Μονοκλωνικα αντισωματα και θραυσματα αντισωματων μονης αλυσιδας εναντιον προστατικου μεμβρανικου αντιγονου κυτταρικης επιφανειαςInfo
- Publication number
- CY1111409T1 CY1111409T1 CY20111100431T CY111100431T CY1111409T1 CY 1111409 T1 CY1111409 T1 CY 1111409T1 CY 20111100431 T CY20111100431 T CY 20111100431T CY 111100431 T CY111100431 T CY 111100431T CY 1111409 T1 CY1111409 T1 CY 1111409T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cell membrane
- surface antigen
- against cell
- monoclonal antibody
- fragments against
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title 1
- 230000000890 antigenic effect Effects 0.000 title 1
- 210000000170 cell membrane Anatomy 0.000 title 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 abstract 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pregnancy & Childbirth (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05011536A EP1726650A1 (en) | 2005-05-27 | 2005-05-27 | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| EP06707388.2A EP1883698B2 (en) | 2005-05-27 | 2006-03-02 | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1111409T1 true CY1111409T1 (el) | 2015-08-05 |
Family
ID=34937022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111100431T CY1111409T1 (el) | 2005-05-27 | 2011-05-04 | Μονοκλωνικα αντισωματα και θραυσματα αντισωματων μονης αλυσιδας εναντιον προστατικου μεμβρανικου αντιγονου κυτταρικης επιφανειας |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8198416B2 (enExample) |
| EP (3) | EP1726650A1 (enExample) |
| JP (4) | JP5038297B2 (enExample) |
| CN (1) | CN101233236B (enExample) |
| AT (1) | ATE505544T1 (enExample) |
| AU (1) | AU2006251445B2 (enExample) |
| CA (1) | CA2609682C (enExample) |
| CY (1) | CY1111409T1 (enExample) |
| DE (1) | DE602006021296D1 (enExample) |
| DK (1) | DK1883698T4 (enExample) |
| ES (1) | ES2362795T5 (enExample) |
| PL (1) | PL1883698T5 (enExample) |
| PT (1) | PT1883698E (enExample) |
| RU (1) | RU2458073C2 (enExample) |
| SI (1) | SI1883698T2 (enExample) |
| WO (1) | WO2006125481A1 (enExample) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
| EP1448588A4 (en) | 2001-10-23 | 2006-10-25 | Psma Dev Company L L C | ANTIBODIES AND MULTIMERS OF PSMA PROTEINS |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| EP1726650A1 (en) | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| GB0715542D0 (en) * | 2007-08-09 | 2007-09-19 | Imp Innovations Ltd | Methods |
| CN101910197B (zh) | 2007-11-30 | 2014-09-24 | 卡罗拜奥斯制药公司 | 针对铜绿假单胞菌pcrv抗原的抗体 |
| WO2009127046A1 (en) * | 2008-04-14 | 2009-10-22 | Proscan Rx Pharma Inc. | Prostate specific membrane antigen antibodies and antigen binding fragments |
| ITTO20080313A1 (it) * | 2008-04-22 | 2009-10-23 | Marco Colombatti | Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi |
| DK2352763T4 (da) | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
| HRP20160684T1 (hr) * | 2008-10-01 | 2016-07-15 | Amgen Research (Munich) Gmbh | Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću |
| US10517969B2 (en) | 2009-02-17 | 2019-12-31 | Cornell University | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| TWI629357B (zh) * | 2009-10-02 | 2018-07-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種特異性的ＰＳＭＡｘＣＤ３雙特異性單鏈抗體 |
| US8772459B2 (en) * | 2009-12-02 | 2014-07-08 | Imaginab, Inc. | J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use |
| TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| RU2632647C2 (ru) | 2011-04-22 | 2017-10-06 | Аптево Рисерч Энд Девелопмент Ллс | Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы |
| WO2013155605A1 (en) * | 2012-04-19 | 2013-10-24 | Innovascreen Inc. | Method for predicting a pathophysiological condition in an animal |
| CN106163547A (zh) | 2014-03-15 | 2016-11-23 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
| CN108367004B (zh) | 2015-09-21 | 2022-09-13 | 阿帕特夫研究和发展有限公司 | Cd3结合多肽 |
| FI3380620T3 (fi) | 2015-11-23 | 2024-08-01 | Novartis Ag | Optimoituja lentiviruksen siirtovektoreita ja niiden käyttötapoja |
| EP4219689A3 (en) | 2015-12-30 | 2023-12-20 | Novartis AG | Immune effector cell therapies with enhanced efficacy |
| CN105968203A (zh) * | 2016-02-03 | 2016-09-28 | 南昌大学 | 一种抗前列腺特异性膜抗原胞外区的单域重链抗体 |
| CN105524171A (zh) * | 2016-02-03 | 2016-04-27 | 中国人民解放军第三军医大学第三附属医院 | 一种针对前列腺特异性膜抗原的纳米抗体 |
| CN105968202A (zh) * | 2016-02-03 | 2016-09-28 | 南昌大学 | 针对前列腺特异性膜抗原胞外区的单域重链抗体 |
| CN105968201A (zh) * | 2016-02-03 | 2016-09-28 | 南昌大学 | 针对前列腺特异性膜抗原的单域重链抗体 |
| CN105504061A (zh) * | 2016-02-03 | 2016-04-20 | 南昌大学 | 针对前列腺特异性膜抗原的纳米抗体 |
| CN105542009A (zh) * | 2016-02-03 | 2016-05-04 | 南昌大学 | 一种针对前列腺特异性膜抗原的单域重链抗体 |
| KR20180118175A (ko) | 2016-03-04 | 2018-10-30 | 노파르티스 아게 | 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도 |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| KR20180134385A (ko) | 2016-04-15 | 2018-12-18 | 노파르티스 아게 | 선택적 단백질 발현을 위한 조성물 및 방법 |
| JP7042467B2 (ja) | 2016-05-20 | 2022-03-28 | ハープーン セラピューティクス，インク． | 単鎖可変フラグメントｃｄ３結合タンパク質 |
| EP3493844A4 (en) | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| EP3490590A2 (en) | 2016-08-01 | 2019-06-05 | Novartis AG | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| MX2019006045A (es) | 2016-11-23 | 2019-11-11 | Harpoon Therapeutics Inc | Proteinas triespecificas dirigidas a psma y metodos de uso. |
| AU2017363300A1 (en) * | 2016-11-23 | 2019-06-20 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
| WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
| EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| EP3577134A1 (en) | 2017-01-31 | 2019-12-11 | Novartis AG | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| US20200048359A1 (en) | 2017-02-28 | 2020-02-13 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| IL300964A (en) | 2017-05-12 | 2023-04-01 | Harpoon Therapeutics Inc | mesothelin binding proteins |
| CN110913908B (zh) | 2017-05-12 | 2022-05-27 | 哈普恩治疗公司 | 靶向msln的三特异性蛋白质及使用方法 |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| CN111630070B (zh) | 2017-10-13 | 2024-07-30 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| TWI829655B (zh) | 2017-10-18 | 2024-01-21 | 瑞士商諾華公司 | 用於選擇性蛋白質降解的組合物及方法 |
| WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
| CN111566124A (zh) | 2017-10-25 | 2020-08-21 | 诺华股份有限公司 | 制备表达嵌合抗原受体的细胞的方法 |
| US20210179709A1 (en) | 2017-10-31 | 2021-06-17 | Novartis Ag | Anti-car compositions and methods |
| EP3724231A4 (en) | 2017-12-12 | 2021-08-11 | MacroGenics, Inc. | BISPECIFIC CD16 BINDING MOLECULES AND THEIR USES IN THE TREATMENT OF DISEASES |
| JP2021521202A (ja) | 2018-04-13 | 2021-08-26 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 固形腫瘍の治療のための標的化されたアマトキシン複合体 |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| MX2020012217A (es) | 2018-05-14 | 2021-03-02 | Harpoon Therapeutics Inc | Porción de unión para activación condicional de moléculas de inmunoglobulina. |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| US20210123075A1 (en) | 2018-06-08 | 2021-04-29 | Novartis Ag | Compositions and methods for immunooncology |
| EP3587454A1 (en) * | 2018-06-27 | 2020-01-01 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors that bind to prostate specific membrane antigen |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| IL279823B1 (en) * | 2018-07-31 | 2025-10-01 | Heidelberg Pharma Res Gmbh | Cultured antibodies against PSMA |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| IL297931B2 (en) | 2018-09-25 | 2025-03-01 | Harpoon Therapeutics Inc | DLL3 binding proteins and methods of use |
| JP2022514315A (ja) | 2018-12-20 | 2022-02-10 | ノバルティス アーゲー | ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ |
| EP3924054B1 (en) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN110407939B (zh) * | 2019-03-12 | 2023-09-29 | 广东医科大学附属第二医院 | 一种人源化抗psma单链抗体及其应用 |
| EP3959320A1 (en) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions and methods for selective protein degradation |
| MX2021014007A (es) | 2019-05-14 | 2022-01-24 | Harpoon Therapeutics Inc | Proteinas de union a epcam y metodos de uso. |
| US20230057071A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| EP3842461A1 (en) | 2019-12-23 | 2021-06-30 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors that bind to prostate specific membrane antigen |
| CN111303288B (zh) * | 2020-03-04 | 2020-12-25 | 和铂医药(苏州)有限公司 | 一种分离的结合抗原psma的蛋白及其用途 |
| WO2021164692A1 (zh) * | 2020-02-18 | 2021-08-26 | 和铂医药(上海)有限责任公司 | 一种分离的结合抗原psma的蛋白及其用途 |
| EP4106806A4 (en) | 2020-02-21 | 2024-07-24 | Harpoon Therapeutics, Inc. | FLT3-BINDING PROTEINS AND METHODS OF USE |
| WO2021252920A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン |
| US20230272110A1 (en) | 2020-07-08 | 2023-08-31 | LAVA Therapeutics N.V. | Antibodies that bind psma and gamma-delta t cell receptors |
| CN116134027B (zh) | 2020-08-03 | 2025-01-24 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125468A1 (es) | 2021-04-27 | 2023-07-19 | Novartis Ag | Sistema de producción de vectores virales |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
| WO2024186656A1 (en) | 2023-03-03 | 2024-09-12 | Arsenal Biosciences, Inc. | Systems targeting psma and ca9 |
| AU2024276994A1 (en) | 2023-05-24 | 2025-10-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2025235801A1 (en) | 2024-05-08 | 2025-11-13 | City Of Hope | Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy |
| CN119735685B (zh) * | 2025-03-04 | 2025-06-13 | 深圳真实生物医药科技有限公司 | 一种靶向前列腺特异性膜抗原的抗体、其抗原结合片段、制备方法及其用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5162504A (en) * | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
| US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| FI953792A7 (fi) * | 1993-02-10 | 1995-08-10 | Unilever Nv | Immobilisoidut proteiinit, joilla on spesifiset sitoutumiskyvyt, ja niiden käyttö menetelmissä ja tuotteissa |
| US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| ATE318147T1 (de) * | 1996-03-25 | 2006-03-15 | Medarex Inc | Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen |
| US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| CA2282836A1 (en) * | 1997-02-26 | 1998-09-03 | Sankyo Company, Limited | Compositions for treating or preventing prostatic cancer |
| US6258939B1 (en) * | 1997-03-10 | 2001-07-10 | The Regents Of The University Of California | PSCA antibodies and hybridomas producing them |
| MXPA02000961A (es) * | 1999-07-29 | 2003-08-20 | Medarex Inc | Anticuerpos monoclonales humanos para antigeno de membrana especifico de la prostata. |
| FR2797743B1 (fr) * | 1999-08-23 | 2003-08-08 | Urogene | Lignee cellulaire prostatique et son utilisation pour l'obtention d'une tumeur prostatique etablie chez l'animal |
| IL158969A0 (en) * | 2001-06-01 | 2004-05-12 | Cornell Res Foundation Inc | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| EP1411983A4 (en) * | 2001-06-26 | 2006-06-21 | Imclone Systems Inc | BISPECIFIC ANTIBODIES BINDING TO VEGF RECEPTORS |
| AU2002305767B2 (en) * | 2001-09-20 | 2008-04-10 | Cornell Research Foundation, Inc. | Methods and compositions for treating and preventing skin disorders using binding agents specific for PSMA |
| EP1448588A4 (en) * | 2001-10-23 | 2006-10-25 | Psma Dev Company L L C | ANTIBODIES AND MULTIMERS OF PSMA PROTEINS |
| EP1519747A4 (en) * | 2002-01-28 | 2006-03-29 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES AGAINST PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) |
| JP2004000045A (ja) * | 2002-05-31 | 2004-01-08 | Kyowa Hakko Kogyo Co Ltd | 前立腺特異的膜抗原に対する抗体 |
| US6641899B1 (en) * | 2002-11-05 | 2003-11-04 | International Business Machines Corporation | Nonlithographic method to produce masks by selective reaction, articles produced, and composition for same |
| WO2004067570A2 (en) * | 2003-01-28 | 2004-08-12 | Proscan Rx Pharma | Prostate cancer diagnosis and treatment |
| EP1841467A4 (en) * | 2005-01-14 | 2009-01-28 | Cytogen Corp | COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES |
| WO2006089231A2 (en) * | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
| JP2008529556A (ja) * | 2005-02-18 | 2008-08-07 | メダレックス， インク． | 前立腺特異的膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体 |
| WO2006110745A2 (en) * | 2005-04-08 | 2006-10-19 | Cytogen Corporation | Conjugated anti-psma antibodies |
| EP1726650A1 (en) | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| DK1912677T3 (da) * | 2005-06-20 | 2014-01-13 | Psma Dev Company L L C | PSMA-antistof-lægemiddel-konjugater |
-
2005
- 2005-05-27 EP EP05011536A patent/EP1726650A1/en not_active Withdrawn
-
2006
- 2006-03-02 AT AT06707388T patent/ATE505544T1/de active
- 2006-03-02 DE DE602006021296T patent/DE602006021296D1/de active Active
- 2006-03-02 CN CN2006800275807A patent/CN101233236B/zh active Active
- 2006-03-02 EP EP11151622A patent/EP2363486A1/en not_active Ceased
- 2006-03-02 JP JP2008512701A patent/JP5038297B2/ja active Active
- 2006-03-02 CA CA2609682A patent/CA2609682C/en active Active
- 2006-03-02 DK DK06707388.2T patent/DK1883698T4/en active
- 2006-03-02 US US11/915,454 patent/US8198416B2/en active Active
- 2006-03-02 PT PT06707388T patent/PT1883698E/pt unknown
- 2006-03-02 ES ES06707388.2T patent/ES2362795T5/es active Active
- 2006-03-02 AU AU2006251445A patent/AU2006251445B2/en active Active
- 2006-03-02 WO PCT/EP2006/001917 patent/WO2006125481A1/en not_active Ceased
- 2006-03-02 PL PL06707388T patent/PL1883698T5/pl unknown
- 2006-03-02 EP EP06707388.2A patent/EP1883698B2/en active Active
- 2006-03-02 RU RU2007147596/10A patent/RU2458073C2/ru active
- 2006-03-02 SI SI200630996T patent/SI1883698T2/sl unknown
-
2011
- 2011-05-04 CY CY20111100431T patent/CY1111409T1/el unknown
-
2012
- 2012-04-13 JP JP2012091882A patent/JP5524270B2/ja active Active
- 2012-05-08 US US13/466,286 patent/US8632777B2/en active Active
-
2013
- 2013-12-13 US US14/105,808 patent/US9238694B2/en active Active
-
2014
- 2014-01-31 JP JP2014017392A patent/JP6110321B2/ja active Active
-
2016
- 2016-03-28 JP JP2016063219A patent/JP2016190839A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111409T1 (el) | Μονοκλωνικα αντισωματα και θραυσματα αντισωματων μονης αλυσιδας εναντιον προστατικου μεμβρανικου αντιγονου κυτταρικης επιφανειας | |
| ES2527961T3 (es) | Anticuerpos monoclonales humanos para CD70 | |
| ES2639026T3 (es) | Anticuerpos totalmente humanos específicos para CADM1 | |
| CY1118709T1 (el) | Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf | |
| NO2017032I1 (no) | bezlotoksumab | |
| PE20100268A1 (es) | Metodos para modificar el punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en la region de determinacion de la complementariedad (cdr) | |
| NZ623541A (en) | Human cgrp receptor binding proteins | |
| NO20071436L (no) | Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater | |
| PH12016501691A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| EA201000910A1 (ru) | Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения | |
| DE60333732D1 (de) | Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen | |
| DK1565489T3 (da) | Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet | |
| ATE517183T1 (de) | Monoklonaler antikörper gegen cd20 | |
| AR078751A1 (es) | Moleculas de anticuerpo anti-gcc (guanililo ciclasa c) y composiciones y metodos relacionados | |
| CR20120587A (es) | Moléculas de unión al antígeno que fijan egfr, vectores que las codifican y uso de las mismas | |
| EA201391159A1 (ru) | Hla-рестриктированные пептидоспецифические антигенсвязывающие белки | |
| CR10656A (es) | Proteinas de union a interleuquina-13 | |
| ATE520716T1 (de) | Humanisierter anti-cd4-antikörper mit immunsuppressiven eigenschaften | |
| AR067199A1 (es) | Proteinas de union a antigenos que se unen a par-2 | |
| EP4253959A3 (en) | Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule | |
| WO2008143702A3 (en) | Anti-mrp3 antibodies and methods of use | |
| WO2022256506A3 (en) | Dkk1/hla-a2 binding molecules and methods of their use | |
| UA106870C2 (uk) | Антитіла, специфічні для протофібрилярної форми бета-амілоїдного білка | |
| TH147612A (th) | โมเลกุลแอนตี้-gcc แอนตี้บอดี้และองค์ประกอบและวิธีการที่เกี่ยวข้อง | |
| CY1115000T1 (el) | Ανθρωπινα αντισωματα εναντια στη λυσσα και χρησεις αυτων |